Results 1 to 10 of about 9,340 (184)
Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence [PDF]
Frontiers in ImmunologyHypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora +6 more
doaj +2 more sources
Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan [PDF]
Scientific ReportsFive-year survival in eosinophilic granulomatosis with polyangiitis (EGPA) exceeds 90%, but long-term prognosis is poor. We examined prognosis in 87 Japanese EGPA patients, seen between April 2018 and December 2024, after mepolizumab introduction ...
Yuga Yamashita +11 more
doaj +2 more sources
Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]
The Korean Journal of Internal MedicineBackground/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim +6 more
doaj +2 more sources
Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma [PDF]
Journal of Allergy and Clinical Immunology: GlobalBackground: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab’s impact on the clinical and health care resource utilization (HCRU) burden ...
Michelle L. Hernandez, MD +6 more
doaj +2 more sources
Annals of MedicineObjectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult ...
Ian Pavord +6 more
doaj +2 more sources
Therapeutic Advances in Respiratory DiseaseBackground: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan. Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral ...
Shih-Lung Cheng +19 more
doaj +2 more sources
Frontiers in Pharmacology, 2023 Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li +3 more
doaj +1 more source
Hospital Pharmacy, 2016 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J +2 more
openaire +3 more sources
Respirology Case Reports, 2023 Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama +9 more
doaj +1 more source
Allergy, Asthma & Clinical Immunology, 2023 Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto +7 more
doaj +1 more source